Clinical efficacy of DC-CIK immunotherapy in treatment of advanced pancreatic adenocarcinoma
10.3872/j.issn.1007-385X.2018.04.014
- VernacularTitle:DC-CIK免疫治疗晚期胰腺癌的临床疗效分析
- Author:
SONG Dong
1
;
YANG Xiaoling
1
;
YANG Xuejing
1
;
FENG Huijing
1
;
ZHANG Junping
1
Author Information
1. Department of Oncology, Shanxi Academy of Medical Science/Shanxi Dayi Hospital, Taiyuan 030032, Shanxi, China
- Publication Type:Journal Article
- Keywords:
DC-CIK;
advanced pancreatic adenocarcinoma;
immunological function;
quality of life [Chin J Cancer Biother, 2018, 25(4): 401-406
- From:
Chinese Journal of Cancer Biotherapy
2018;25(4):401-406
- CountryChina
- Language:Chinese
-
Abstract:
［ ［Abstract］ ］Objective: To analyze and compare the clinical efficacy and safety of dendritic cell cytokine-induced killer cells (DCCIK) combined with palliative therapy or chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: A retrospective study was carried on 50 patients with advanced pancreatic carcinoma who were hospitalized in department of oncology of Shanxi Dayi Hospital during September 2012 to February 2016. The patients were divided into four groups according to the therapy they received (palliative treatment group, palliative+DC-CIK treatment group, chemotherapy group and chemotherapy+DC-CIK treatment group); the immunological function, quality of life and survival time of patients were analyzed; and the efficacy and safety of DC-CIK cell therapy was also evaluated. Results: The percentages of CD8+ T cells and NKT cells in DC-CIK combined therapy groups were significantly improved compared with that of pre-treatment, and the percentages of CD3+, CD8+, NK, NKT cells were increased compared with control groups (P<0.05). The quality of life of patients was significantly improved (P<0.05), while median PFS and median OS were improved but without statistical significance (P>0.05). Conclusion: Compared with palliative therapy and chemotherapy alone, combined DC-CIK immunotherapy can effectively improve the cellular immunity function and quality of life in patients with advanced pancreatic cancer. However, there was no significant extension in overall survival.
- Full text:20180414.pdf
